The place of inhaled corticosteroids in chronic obstructive pulmonary disease

Current Medical Research and Opinion

Volumn 20, Issue 10, 2004, Pages 1579-1593

  Selroos, Olof ^a,b,c,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b LUND UNIVERSITY   (Sweden)

^c Mjolbolsta Hospital   (Finland)

^d Department of Pulmonary Medicine ^*  (Sweden)

Author keywords

COPD; Efficacy; Exacerbations; Inhaled corticosteroids; Long acting 2 agonists; Tolerability

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID;

ACNE; ADRENAL CORTEX INSUFFICIENCY; BEHAVIOR DISORDER; CANDIDIASIS; CAPILLARY RESISTANCE; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CATARACT; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DISABILITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; EMBASE; EPIDEMIOLOGICAL DATA; FORCED EXPIRATORY VOLUME; FRACTURE; GASTROINTESTINAL DISEASE; HEMATOMA; HOARSENESS; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LUNG FUNCTION; MEDLINE; MENTAL DISEASE; META ANALYSIS; METABOLIC DISORDER; MOON FACE; MORTALITY; MYOPATHY; OSTEOPOROSIS; QUALITY OF LIFE; REVIEW; SORE THROAT; SYSTEMATIC REVIEW;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; CLINICAL TRIALS; EPIDEMIOLOGIC STUDIES; HEALTH STATUS; HUMANS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 7644231598     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X3708     Document Type: Review

References (59)

1. Niewoehner DE. The role of systemic corticosteroids in acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Med 2002;1:243-8
2. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999;354:456-60
3. Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002;165:698-703
4. Mirici A, Meral M, Akgun M. Comparison of the efficacy of nebulised budesonide with parenteral corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Drug Invest 2003;23:55-62
5. Calverley PMA. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:341-2; discussion 344
6. Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:342-4; discussion 344
7. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002;113:59-65
8. Jackevicius CA, Chapman KR. Prevalence of inhaled corticosteroid use among patients with chronic obstructive pulmonary disease: a survey. Ann Pharmacother 1997;31:160-4
9. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998;157(Suppl 3 Pt 2):S1-S53
10. Dompeling E, van Schayck CP, Molema J, Folgering H, van Grunsven PM, van Weel C. Inhaled beclomethasone improves the course of asthma and COPD. Eur Respir J 1992;5:945-52
11. Kerstjens HAM, Brand PLP, Hughes MD, et al. A comparison of bronchodilator therapy with and without inhaled corticosteroid therapy for obstructive airway disease: Dutch Chronic Non-specific Lung Disease Study Group. N Engl J Med 1992;327:1413-9
12. 1 in patients with chronic obstructive pulmonary disease: results of a 2-year prospective multicentre study. Am J Respir Crit Care Med 1995;151:A463
13. Renkema TEJ, Schouten JP, Koeter GH, Postma DS. Effects of long-term treatment with corticosteroids in COPD. Chest 1996;109:1156-62
14. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998;351:773-80
15. Bourbeau J, Rouleau MY, Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 1998;53:477-82
16. Weir DC, Bale GA, Bright P, Sherwood Burge P. A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clin Exp Allergy 1999;29(Suppl 2):125-8
17. Senderovitz T, Vestbo J, Frandsen J, et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. Respir Med 1999;93:715-8
18. van Grunsven PM, van Schayck CP, Derenne JP, et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999;54:7-14
19. Vestbo J, Sørensen T, Lange P, Brix A, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23
20. Pauwels RA, Löfdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999;340:1948-53
21. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303
22. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9
23. 1. JAMA 1994;272:1497-505
24. 1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 2003;138:969-73
25. Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003;58:937-41
26. 1 in patients with COPD after all? Thorax 2003;58:911-3
27. Selroos O. The effects of inhaled corticosteroids on the natural history of obstructive lung diseases. Eur Respir Rev 1991; 1:369-78
28. Dirksen A, Christensen H, Evald T, et al. Bronchodilator and corticosteroid reversibility in ambulatory patients with airways obstruction. Dan Med Bull 1991;38:486-9
29. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003;58:654-8
30. Calverley PMA, Burge PS, Spencer S, Anderson JA, Jones PW Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003;58:659-64
31. Jarad NA, Wedzicha JA, Burge PS, Calverley PMA. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir Med 1999;93:161-6
32. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. The COPE study. Am J Respir Crit Care Med 2002;166:1358-63
33. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003;21(Suppl 41):46s-53s
34. Pauwels R, Calverley P, Buist AS, Rennard S, Fukuchi Y, Stahl E, Lofdahl CG. COPD exacerbations: the importance of a standard definition. Respir Med 2004;98:99-107
35. Vestbo J. What is an exacerbation of COPD? Eur Respir Rev 2004;13:6-13
36. Jones PW, Willits LR, Burge PS, Calverley PMA. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21:68-73
37. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81
38. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56
39. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-9
40. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:580-4
41. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996;49:1429-33
42. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002;20:819-25
43. Soriano JB, Kiri VA, Pride NB, Vestbo J. Inhaled corticosteroids with/without long-acting β-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003;2:67-74
44. Sin DD, Man SF. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur Respir J 2003;21:260-6
45. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease. Immortal time bias in observational studies. Am J Respir Crit Care Med 2003;168:49-53
46. Sin DD, Man SF, Tu JV. Inhaled glucocorticoids in COPD: immortal time bias. Am J Respir Crit Care Med 2003;168:126-7
47. Spencer MD, Vestbo J, Soriano JB. The beneficial effects of inhaled corticosteroid use in observational studies of COPD are unlikely to be explained by unmeasured confounders. Am J Respir Crit Care Med 2003;167:A90
48. Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004;116:325-31
49. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-91
50. Dal Negro RW, Pomari C, Tognella S, Micheletto C. Salmeterol and fluticasone 50 μg/250 μg bid in combination provides a better long-term control than salmeterol 50 μg bid alone and placebo in COPD patients already treated with theophylline. Pulm Pharmacol Ther 2003;16:241-6
51. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003;124:834-43
52. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: NHLBI/WHO workshop report. NIH publication No. 2701. Bethesda: US Department of Health and Human Services, 2001
53. Bonay M, Bancal C, Crestani B. Benefits and risks of inhaled corticosteroids in chronic obstructive pulmonary disease. Drug Saf 2002;25:57-71
54. McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest 1997;111:732-43
55. Walsh LJ, Lewis SA, Wong CA, et al. The impact of oral corticosteroid use on bone mineral density and vertebral fracture. Am J Respir Crit Care Med 2002;166:691-5
56. Hubbard RB, Smith CJP, Smeeth L, Harrison TW, Tattersfield AE. Inhaled corticosteroids and hip fractures. A population-based case-control study. Am J Respir Crit Care Med 2002;166:1563-6
57. Johnell O, Pauwels R, Löfdahl CG, et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J 2002;19:1058-63
58. Capewell S, Reynolds S, Shuttleworth D, Edwards C, Finlay AY. Purpura and dermal thinning associated with high dose inhaled corticosteroids. Br Med J 1990;300:1548-51
59. Mak VHF, Melchor R, Spiro SG. Easy bruising as a side-effect of inhaled corticosteroids. Eur Respir J 1992;5:1068-74